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Objectives: The primary objective of this pilot study was to determine if the Medication Event 
Monitoring System (MEMS) is capable of providing meaningful estimates of compliance within 
the indigenous Qatari population. The secondary objective was to highlight any specific problems 
which might be associated with the use of MEMS within this population.
Method: A sample of adult diabetic Qatari patients attending an outpatient diabetic clinic were 
administered a Knowledge, Attitude, and Practices (KAP) questionnaire and then dispensed 
one of their regular medications in a MEMS®-fitted bottle. Data contained in the MEMS® were 
downloaded after the patients returned for a refill and adherence was estimated using 2 methods: 
pill count and MEMS® data.
Results: A total of 54 patients agreed to participate in this pilot study. Adherence to daily doses 
was 67.7% and with regimen 13.7%. No correlation was found between adherence assessed 
by pill count and MEMS®. The association between KAP and adherence was generally poor. 
A number of other issues and challenges in the use of MEMS® that could affect its utility were 
noted and will be discussed.
Conclusions: Our results revealed problems associated with the use of MEMS® that could 
affect its usefulness in assessing adherence in this part of the world. Some issues identified in 
this pilot study included retrieving the MEMS®, registering extra opening of MEMS®, desire to 
hoard medicine by taking doses at different frequency than recorded in MEMS®. All these issues 
could be closely associated with the attitudes and practices of the patients, as demonstrated by 
our KAP analysis and correlations.
Keywords: Medication Events Monitoring System (MEMS), type 2 diabetes mellitus, drug 
therapy, medication adherence
So far there is no accepted “Gold Standard” to objectively assess adherence with drug 
therapy. Strategies to assess adherence include self-reporting, pill-counting, and the use 
of the Medication Event Monitoring System, or MEMS®. To our knowledge, the latter 
method had not previously been tested in the Gulf country region. There is little doubt 
that pharmacotherapeutic (or pharmacological) agents remain the most used treatment 
modality for the management of disease,1 which means that successful pharmacologi-
cal treatment of illness (especially chronic illness) would be significantly influenced 
by the extent to which patients comply with (or adhere to) their medication regimens. 
Adherence with medication therapy was defined as the degree or extent of conformity 
to the recommendations made regarding day-to-day treatment by the   provider with 
respect to the timing, dosage, and frequency with prescribed medication.2 The problem 





However, the assumption by many healthcare providers that 
nonadherence can easily be detected by the treating physician 
had not been substantiated.6 On the contrary, results of recent 
studies showed that physicians could not predict adherence 
with any more accuracy than if they were guessing.7 Several 
factors that might lead to poor adherence were reported in the 
literature. Lack of patient information about their disease or 
its treatment, adverse effects of prescribed drugs, the patient’s 
dissatisfaction with their health condition, the personality 
of the patient, the disease, and the treatment (cost and 
complexity).7,8–10 Assessing adherence presents an ongoing 
challenge. Although several methods are used to estimate and 
quantify adherence, accurate measurement continues to be 
difficult, especially when studying populations with unique 
cultural traditions and geographical situations.
Attempts to measure nonadherence more objectively 
have stimulated the development of a wide spectrum 
of methodologies and provided a considerable body of 
descriptive and analytic literature. These strategies fall into 
three main categories: measuring biological serum levels of 
the medication to check if the doses prescribed were actually 
taken by the patient, using data derived from dispensing 
records, and gauging information directly from the patient 
to infer the degree of adherence.11–14
The later method is operationalized using three basic 
techniques: self-reporting,a pill-counting, and the use of 
electronic adherence assessment devices. One such device is 
the Medication Event Monitoring System15 (MEMS®). Using 
biological assays to measure the concentration of a drug or 
its metabolites is intrusive, burdensome to the patient, and 
often costly.16 Drug and food interactions,   physiological 
  differences, and the half-life of the drugs all complicate 
the measurement and may diminish reliability. Estimating 
adherence based on data derived from dispensing records 
is faced with concerns related to data completeness and 
data records reliability. Patient self-assessed adherence to 
drug therapy relies on interviewing patients to assess their 
  knowledge of the medications and the dosing schedule 
provides little information and is liable to be affected by 
interviewer bias.2,17 Counting the remaining number of pills of 
a patient who returns for a refill presents an easy method for 
assessing adherence, but is not free of problems. For example, 
Grymonpre and coworkers suggested that pill count may 
underestimate patient adherence in older populations, because 
pill counts are often based upon the date a prescription is 
filled, patients who get prescriptions refilled prior to their first 
one running out and then combining pills into a single (and 
possibly nonoriginal) bottle presents complications.
The MEMS® is an electronic innovation that brings 
modern technology and an element of objectivity to the assess-
ment of patient adherence. This is an alternative approach to 
the study of adherence and – as with all methods – there are 
aspects of the technique which may potentially to introduce 
bias and misunderstanding into the interpretation of results.b 
For example, it cannot distinguish a missed dose from one 
doubled at the next bottle opening (so that patient diaries have 
been advocated14 as a suitable adjunct to method). Clearly, one 
fundamental weakness of the MEMS® is also its inability to 
distinguish between cap openings in which a dose is or is not 
removed. However, in spite of these shortcomings, a growing 
number of investigators are taking a MEMS® path to the study 
of adherence although the analysis and interpretation of the 
results have stimulated a wide variety of approaches.
However, although this technique has been used 
successfully within Western populations for the last 10 years, 
to our knowledge it had not been applied to any population 
in the Arabian Gulf or the wider Middle East. Given the 
significant number of potential pitfalls which are associated 
with MEMS®, we decided that – prior to embarking on our 
full study (aimed at estimating the prevalence of adherence 
among Qataris, in a variety of circumstances) – it was first 
necessary to validate the technique within the Arabian Gulf. 
Therefore the two primary objectives in this pilot study were: 
(a) to investigate the capability of MEMS® for accurately 
estimating adherence with drug therapy in the context of 
type 2 diabetes mellitus (T2DM) within the Qatari population 
of the Arabian Gulf by comparing parallel estimates of pill 
counts and indications from the questionnaires, and (b) to 
assess the value of the questionnaires in suggesting possible 
reasons for any lack of adherence. We were also interested in 
identifying any specific local factors which might compro-
mise the practicality of applying the MEMS-based technique 
(and associated questionnaires) to this population.
Methods
This study was approved by the Institute Review Board in 
Hamad Medical Corporation (Doha, Qatar) in October 2008.
study protocol
All adult Qatari patients with a confirmed diagnosis of T2DM 
and who had scheduled visits at the Endocrinology Outpatient 
aStructured interviews, questionnaires, or diaries.
beg, “Curiousity events” where patients demonstrate novel features of the 




Utility of MeMs in Qatar
Clinic at Hamad General Hospital were identified prior to their 
appointment and offered the opportunity to enroll in the study 
by the physician if they were prescribed the oral anti-diabetic 
medication metformin. Trained research assistants discussed the 
consent process with the patients; the patients were informed 
that the purpose of the study was to assess the usability of new 
medication containers which were intended to improve the 
efficiency of the treatment of diabetes at the hospital. Those 
who consented were administered a Diabetes Habits and Beliefs 
Questionnaire (DHBQ). Any other medications prescribed to 
the patient were packaged in their usual containers.
Before leaving the pharmacy, all enrolled patients were 
asked to: (i) to take all future doses of metformin only from 
the serially numbered MEMS® bottle (containing one month’s 
supply), (ii) to return the MEMS® bottle to the outpatient 
pharmacy in one month’s time (in order to obtain a refill), 
(iii) to only to take the prescribed dose each time the bottle was 
opened, and (iv) to return the bottle with all remaining pills 
(if any). During the follow-up appointment, the medication 
bottle and MEMS® were retrieved and a short MEMS® satis-
faction questionnaire was administered to assess the patient’s 
experience in using the MEMS®. Data contained in the 
MEMS® were then downloaded using MEMS® software and 
the number of remaining pills was documented. Arabic ver-
sions of all questionnaires were used throughout this study.
Questionnaires
This 51-item DHBQ questionnaire was adapted from the 
Diabetes Time Management Questionnaire created by 
Gafarian et al (1999) which had been specifically developed 
to assess beliefs, general time management skills, and 
areas specifically relevant to adherence to diabetes therapy 
regimens.18 The DHBQ also contained questions adapted 
from the Hospital Anxiety and Depression Scale, an 
instrument that was originally developed as a self-assessment 
scale for detecting states of depression and anxiety in an 
outpatient setting.19 During questionnaire development, the 
translated version of the DHBQ was tested for its face validity 
and cultural adaptability within a small group of Qatari 
diabetic patients not taking part in the study. In addition 
to basic demographics information (age, marital status, 
highest education, and employment category) the DHBQ 
Questionnaire contained the following 47 items:
•	 (8) questions: diabetes general knowledge
•	 (14) questions: diabetes-related activities (practice)
•	 (6) questions: time-management (habits)
•	 (9) questions: attitude to living with diabetes
•	 (10) questions: depression status (mood)
Each of these questions was rated on a 7-point Likert 
scale, and the overall score for each category was obtained 
by summing the individual responses.
The time since diagnosis (TSD) with diabetes was 
retrieved from each patient’s medical record shortly after 
the face-to-face interviews. The MEMS® User Satisfaction 
Questionnaire comprised three questions: (i) How easy is it 
for the patient to use the MEMS, (ii) Did the patient use the 
MEMS as their only source for metformin, and (iii) Did the 
patient ever open the container and not take a dose.
Medication event Monitoring systems 
(MeMs®)
The Medication Event Monitoring Systems (MEMS®; 
APREX, Division of AARDEX, Union City, CA) uti-
lizes drug packaging with electronic circuitry to compile 
ambulant patient medication dosing histories.20 Each 
monitor records information pertaining to the times that 
the medication container is opened and closed (medica-
tion events). The MEMS® is simply a standard medication 
container bottle whose cap is fitted with a microprocessor 
that records every bottle opening. These real-time data are 
stored on the MEMS® and can later be uploaded to a com-
puter. In this study only one medication (metformin) was 
monitored using MEMS® because it was felt that it would 
be impractical and burdensome to use multiple MEMS® 
and prior research has demonstrated that monitoring one 
medication with the MEMS® provides a valid indicator 
that patients took all of their medications.21 Metformin was 
selected as the medication to be investigated because it can 
have different dosing frequencies (once, twice, or thrice 
daily regimens) and because it is frequently prescribed to 
T2DM patients. Data for analyses were exported from the 
MEMS® database into the JMP statistics package (SAS 
Institute, Cary, NL, USA). The events were then aggregated 
into sets of same-day events and displayed in day-of-year 
order for each study participant. The number of opening 
events per day was recorded for all days within a 30-day 
window beginning at the first patient event of the trial. The 
total number of events per patient was also recorded and 
zeros were inserted for days which had no recorded open-
ing events. Any opening within 15 minutes of the previous 
opening was ignored.
Measurements of adherence
Three independent measures of adherence were obtained: (i) 
MEMS® dosage adherence (MEMSd) which is the   percent 





of doses prescribed, (ii) MEMS® regimen adherence rate 
(MEMSr) which is the percentage of days in which the dose 
regimen (measured as bottle openings) was executed as 
prescribed,22 (iii) Pill count was reexpressed as a percentage: 
(1- (No.
returned/No.
prescribed)) × 100%. A threshold value of accept-
able adherence of 80% was used for all three measures.
statistical analysis
The data were analyzed using JMP (version 5) and SPSS® 
(version 17); scientific plots and figures were produced 
using Origin (Microcal v5.1). Two-group comparisons were 
assessed using t tests (where permissible); otherwise the 
nonparametric Mann–Whitney test was used. Differences 
between multiple groups were assessed using one-way analy-
sis of variance. Correlations and intercorrelations between 
questionnaire scores and adherence estimates were estimated 
using simple pairwise correlation coefficients and Spearman’s 
nonparametric correlation coefficient. Statistical significance 
was taken throughout to be P , 0.05.
Results
Fifty-four patients agreed to participate, of whom the major-
ity (61%) were female. The median age was 51 years (mean 
50, SD 9.6), and most patients were married. Because of 
logistical problems (mainly related to a limited budget 
assigned for purchasing of equipment in the pilot study), 
only 37 out of the total patients enrolled in this study were 
issued their medication in MEMS® containers (68%). The 
responses to the MEMS® satisfaction questions (administered 
at the second visit when the patients returned the MEMS®) 
showed that 90% of the patients who were administered the 
questionnaire found the bottle with the MEMS® cap easy to 
handle, and 86% of patients said they used the MEMS® as 
the only source for their prescribed metformin. Furthermore, 
94% of patients said that they opened the container only to 
take a dose of their medicine. However, only 57% of the total 
number of patients who were handed MEMS® responded to 
this questionnaire.
MEMS® retrieval
Out of 37 patients provided their medication in MEMS-capped 
bottles, 13 (35%) patients returned their medicine bottles 
later than the refill date. The mean number of late days 
was 13 (SD = 17.6). Six patients (22%) failed to return 
the MEMS® despite multiple follow-up calls. One patient 
admitted that she threw the bottle filled with MEMS® in 
the trash bin.
Adherence results
Thirty seven MEMS® units were handed out to participants 
with the prescribed metformin tablets but adherence was 
assessed for only the 27 patients who returned their units. 
Quantification for the degree of adherence for these patients 
was computed as MEMSd (% number of bottle openings 
divided by the total number of doses prescribed), and MEMSr 
(% days in which the dose regimen was taken, measured as 
bottle openings by the total number of days for which the 
medication was prescribed).
The number of times the MEMS® was opened ranged 
between 9 and 155 per patient (Median = 70; Mean = 68.63; 
SD = 39.34; SEM = 7.57). The number of days when 
the MEMS® was used by the patients ranged from 2 to 
42 per patient (Mean = 26.52; SD = 11.22; SEM = 2.16; 
Median = 29). Overall adherence with daily doses (MEMSd) 
was 67.7% (SE = 6.9; Median = 82.2%). Overall adherence 
with regimen was 13.7% (SE = 1.9; Median = 15.0%). 
Frequency of distribution of adherence as percentage for 
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MEMS®-measured adherence: 
correlations
Table 1 summarizes correlations between adherence 
(MEMSd and MEMSr) with the five domains (Knowledge, 
Attitude, Practices, Habits, and Depression) as measured 
using the respective questionnaires. The only significant 
correlation was observed between adherence with practices 
in respect to diabetes time management, suggesting that as 
time management improves, so does adherence with the 
antidiabetic medication.
Pill count
Pill counts were performed when each MEMS® unit was 
returned. The range of pills returned was 0–78, with a mean 
of 6.74 (SD = 16.19, SE = 3.12, Median = 0). Adherence was 
estimated using the pill count method, and it was calculated 
to be 91.3% (SE = 18.6; Median = 100.0%). There was no 
significant correlation between the adherence as assessed by 
pill count and any of the other variables.
Discussion
Poor adherence with drug therapy is a significant, 
  widespread problem among all levels of patients and across 
disease states, age groups, and other patient group charac-
teristics.22 In a review of studies published in the period 
from 2002 until 2008, Cramer and colleagues looked at 
the problem of poor adherence among patients with dia-
betes and other cardiovascular diseases, and found that 
the average 12-month adherence rate was 63% and that it 
was similar across therapeutic classes.23 They concluded 
that good adherence had a positive effect on outcome in 
73% of the studies examining clinical outcomes. With this 
and other similar reports in mind, and with consideration 
to the fact that diabetes, specifically T2DM, is on the rise 
globally and in Qatar, our intention was to conduct a fact-
finding study looking at one of the methods for objectively 
assessing adherence with T2DM in Qatar. The available 
methods for estimating adherence all have their limitations, 
and logistical challenges for conducting such a study were 
unknown.
The main objective of this pilot study was to examine the 
usefulness or utility of the MEMS® in an adherence study and 
to identify any issues that affect its usage in such context.
Only 37 patients were issued their medication in MEMS-
fitted bottles. This was partly because a proportion of patients 
failed to return MEMS® in time for re-cycling. We assessed 
patients’ satisfaction with MEMS®, a new medicine bottle 
with which the patient was unfamiliar. Based on a short 
  questionnaire, the majority of patients found it easy to 
use. The bottles fitted with the MEMS® differ in terms of 
size, looks, and the way it has to be opened. Despite these 
  differences, it was clear that patients did not find it difficult to 
handle. However, the MEMS® satisfaction questionnaire was 
administered to a little more than half of the participants.
MEMS® retrieval has proved to be a challenge and an 
issue of potential impact in adherence studies. First, the 
researchers had to limit the amount of information related 
to the MEMS® to the minimum to avoid compromising the 
sensitivity of the measured outcome of adherence through 
a Hawthorne effect.24 As a result, a portion of patients must 
have dealt with the MEMS-fitted containers as they would 
with any other medicine bottle, and either delayed returning 
them or lost them. As a result, 22% of the MEMS® units were 
not returned, and 35% were returned late, some after several 
reminders. The problem was compounded by the fact that, at 
over US$100.00 per 1 unit, MEMS® is a costly commodity 
to lose in bulk. To minimize the potential for the occurrence 
of this problem one has to reexamine how MEMS® was 
issued and the quality of communication the pharmacist 
and/or the research assistant have had with the patient. As 
part of the methodology, four pieces of advice were given 
to the patient during the dispensing process: that the patient 
uses the issued medication bottle as the only source for their 
metformin; that the patient returns the medication bottle to 
the outpatient pharmacy in one month’s time at the date for 
the refill; that the patient opens the bottle only to take the 
Table 1 correlations between compliance with KAP domains1
MEMS® 
compliance























Notes: 1Correlations measured as Pearson correlation coefficients, P , 0.05 indicates statistical significance; 2MeMsd: compliance measured as a factor of daily dosage; 





prescribed dose; and that the patient returns the bottle (with 
MEMS® cap on) with all remaining pills (if any). Apparently 
some of these instructions were either not fully compre-
hended or were not perceived as important by some of the 
participants. Additionally, as we have seen in the rest of the 
results, there was evidence that patients opened the MEMS® 
repeatedly at intervals too close to each other to be counted 
as an event to take a dose (number of openings ranged from 
9 to 155 per patient from the date of dispensing until the 
date when MEMS® was returned). This, as we shall discuss 
further below, must have had an impact on the reliability of 
the MEMS® in the circumstances of measuring adherence. 
To minimize potential for loss or delay of returning of the 
MEMS® units, a focused dialog with the patient (at the time 
of dispensing) where the patient clearly commits to return-
ing the MEMS® on time and using it properly needs to be 
conducted by appropriately trained individuals. This must be 
combined with scheduled reminder phone calls (prior to the 
refill date and preferably at weekly intervals).
The use of MEMS® presented us with several challenges 
in relation to interpretation of results and devising methods 
for optimum usage in clinical trial environments. We have 
already alluded to the problem of retrieval of the costly 
MEMS® units and provided suggestions on how to minimize 
potential loss of the units and their stored data. The second 
group of challenges was related to other issues, including 
quality and interpretation of data.
MEMS® estimated adherence was computed using two 
approaches. The first was through assessing adherence with 
the doses per day (MEMSd). This method considered whether 
the patient took the daily doses as prescribed (ie, once, 
twice, or three times a day). A patient might be prescribed 
metformin twice a day, but s/he took it only once a day. The 
estimated adherence MEMSd in this case would be 50% 
(ie, ½*100%). The result of adherence with dosage (MEMSd) 
had been found to be 67.7%. This is around 20% less than 
the 80% cut-off point for an acceptable adherence. The figure 
of 80% is commonly used and clinically relevant cutoff 
point which had been considered to have reasonable balance 
between sensitivity and specificity in studies of adherence in 
patients with cardiovascular diseases.25
However, adherence with dosage regimen (ie, adherence 
in respect of the days where the regimen was 100% followed, 
or MEMSr) gave adherence levels of only 13.7%. The inter-
pretation of this poor result was most probably due to the 
‘zero tolerance’ approach this assessment method follows. 
To clarify, consider the patient above who was prescribed a 
dose to be taken twice a day but took it only once a day. His 
or her estimated MEMSd was 50%, but his or her MEMSr 
in this case will be zero. Because s/he did not completely 
comply with the daily regimen of two per day, s/he basi-
cally had no score. We have noticed repeated occurrences 
of this behavior, supported by the statistics, where some 
patients started taking regular doses (documented by MEMS® 
opening events) that were not in line with the prescribed dose 
(ie, patients prescribed one tablet three times a day but they 
took one tablet twice a day every day). This had a big impact 
on the adherence as a factor of the regimen.
There are at least two possibilities for this poor MEMSr 
phenomenon. The first is a practice of intentional nonad-
herence. This had been discussed in previous publications, 
and Johnson referred to it as the intentional decision to 
miss medications.26 This is where patients decide to take a 
drug at intervals or at dosages that do not correspond with 
prescribing instructions. The patient might be exercising a 
sort of   personal autonomy or self-rule, reflected in this sort 
of   medication-taking behavior which in turn might be due 
to   previous experience with a specific medication (adverse 
effects, effectiveness at a specific dose, and so on). The   second 
possibility is what could be termed intentional prescribing 
error, where some physicians might be   verbally telling the 
patient to take a specific dose at a specific frequency (eg, one 
tablet once per day), but prescribing another dosage frequency 
(one tablet three times per day). The reason for this is usually 
to get the pharmacy to issue more stock of medication to the 
patient so s/he does not have to come frequently for refills. 
If this is the case, we would be registering in our study the 
prescribed dose as the benchmark to estimate adherence, but 
the patient would open the MEMS® at a rate that is less than 
the registered dose (based on his agreement with the prescrib-
ing physician), and the net result would be poor adherence 
(both with dose and regimen). However, we have no solid 
evidence for this apart from clinical experience, in addition 
to oral and informal communications with pharmacists and 
patients outside the frame of this project.
Another observation from the MEMS® data was the 
number of times the MEMS® was opened by the patient 
(range: 9–155 times per patient) and the number of days 
when the MEMS® was used by the patients (range: 2 to 
42 per patient). The maximum expected total number of 
opening per patient in a month should have been 90 times 
(calculated as one tablet three times a day for one month). 
The large number of openings that occurred meant that 
patients opened the container more that they should have. 
We cannot know when a dose was taken and when it was not 
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MEMS® was used provides an interesting figure of 2–42. 
While the 42 days simply meant a delay in returning the 
unit (and probably also an indication of poor adherence), the 
2 day figure meant either the medication was used scarcely 
or it was used, but from another source. Both possibilities 
indicate violation to our agreement with patients at the 
beginning of the study.
Because of these irregularities in the use of MEMS®, it 
was not surprising that correlation of adherence with other 
patient-related variables were inconsistent with intuition 
or logic. Based on the statistical operations used, no asso-
ciation of significance was observed with adherence as 
measured by the MEMS® and age, years since diagnosis 
(YSD), gender, or education status. When correlated with 
KAP variables, adherence only showed an association with 
practices (time management and habits). This last set of 
correlations made some sense, as one would expect those 
patients who are organized and adhere to certain daily 
routines would also exhibit better adherence with their 
medications.
Adherence as measured from pill count data was over 
90%. This basically meant that most of the patients returned 
no or very few tablets at the time of their refill. However, this 
outcome cannot be taken at face value. First, correlations 
with adherence as measured by pill count and as measured 
by MEMS® were insignificant. One would expect that these 
two methods correlate strongly since the doses taken from 
the MEMS-fitted containers would automatically be counted 
as an event supporting adherence, and will be missing when 
tablets are counted, again supporting adherence. In the 
absence of positive correlation between the two methods, 
the fact that the majority of patients returned empty bottles 
could not be taken as strong evidence of adherence. The pos-
sible reason for the empty containers could be due to patients 
emptying their medications in other containers and bringing 
the MEMS-fitted bottles back, not thinking this would matter. 
This is another demonstration of the importance of a strong 
emphasis on the correct methods participants in this study 
should follow.
The data generated by MEMS® and the observations 
related to it in this pilot study presented us with more question 
than answers. We could not, for example, attribute MEMS® 
cap opening events to doses taken with any confidence, and 
the number of tablets taken at each event remains an assump-
tion. However, the findings and observations will at least help 
in recommending a number of pre-requisites that can maxi-
mize the expected benefits of the MEMS® if it is to be used 
to measure adherence in future clinical trials. An important 
direct outcome of this study would be the cost-savings that it 
will make when we use the experience we gained into a future 
adherence study. We could use the information and lessons 
learnt in this project to minimize potential loss of MEMS®, 
improve the participant’s adherence to the study protocols, 
and maximize the quality of information gained. One of the 
major limitations of this study is the small sample size, thus 
results may not be generalizable. However, the study is a 
pilot; as such it achieved its objective by providing data that 
will help in designing larger studies in which the challenges 
and lessons identified in the current pilot project would be 
addressed. We have also not attempted to assess, through 
correlation statistics, any association that might have existed 
between the number of medications taken by patients and 
other patient and regimen-related factors (apart from the KAP 
domains) with adherence, where our intention in this pilot 
study had been specifically directed towards understanding 
how the electronic device used to assess adherence might be 
applied to the local population rather than assessing adher-
ence as an end point. Therefore, the factors which we were 
primarily concerned with here, and which are reported in 
this manuscript, may not have been previously reported in 
this region.
Conclusion
The utility of MEMS® in assessing adherence remains elu-
sive. Results gained in this study provide strong evidence that 
for the MEMS® to generate valid, reliable, and useful data 
in assessing adherence, it has to be supported by a strong, 
focused, and structured method for patient orientation and 
follow-up. This is especially true because of the inability of 
the study team to explain the real objective of the study to 
the patient (ie, to assess adherence). This limitation presents 
real threats to any similar study, not least the retrieval of 
the MEMS®, registering extra opening of MEMS®, desire 
to hoard medicine by taking doses at different frequency 
than recorded in MEMS®. The overall outcome of this pilot 
study was considered to be achieved, and the application of 
improved methodology in future research is now possible 
largely because of the insights and lessons this project has 
provided us with.
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